181 related articles for article (PubMed ID: 34645517)
1. FDG-PET/CT imaging for evaluating durable responses to immune check point inhibitors in patients with advanced cutaneous squamous cell carcinoma.
McLean LS; Cavanagh K; Hicks RJ; Callahan J; Xie J; Cardin A; Lim AM; Rischin D
Cancer Imaging; 2021 Oct; 21(1):57. PubMed ID: 34645517
[TBL] [Abstract][Full Text] [Related]
2. The Prognostic Role of [
Filippi L; Proietti I; Petrozza V; Potenza C; Bagni O; Schillaci O
Cancer Biother Radiopharm; 2024 Feb; 39(1):46-54. PubMed ID: 37883658
[No Abstract] [Full Text] [Related]
3. Restaging [
Mahajan S; Barker CA; Mauguen A; Singh B; Pandit-Taskar N
J Am Acad Dermatol; 2020 Apr; 82(4):878-886. PubMed ID: 31562942
[TBL] [Abstract][Full Text] [Related]
4. Assessment of perineural spread in advanced cutaneous squamous cell carcinomas treated with immunotherapy.
Cavanagh K; McLean LS; Lim AM; Cardin A; Levy SM; Rischin D
Cancer Imaging; 2024 Mar; 24(1):37. PubMed ID: 38500235
[TBL] [Abstract][Full Text] [Related]
5. Clinical value of 18F-FDG-PET/CT in staging cutaneous squamous cell carcinoma.
Mahajan S; Barker CA; Singh B; Pandit-Taskar N
Nucl Med Commun; 2019 Jul; 40(7):744-751. PubMed ID: 31095044
[TBL] [Abstract][Full Text] [Related]
6. FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma.
Tan AC; Emmett L; Lo S; Liu V; Kapoor R; Carlino MS; Guminski AD; Long GV; Menzies AM
Ann Oncol; 2018 Oct; 29(10):2115-2120. PubMed ID: 30137228
[TBL] [Abstract][Full Text] [Related]
7. Prediction of response to immune checkpoint inhibitor therapy using 18F-FDG PET/CT in patients with melanoma.
Amrane K; Le Goupil D; Quere G; Delcroix O; Gouva S; Schick U; Salaun PY; Abgral R; Alavi Z; Keromnes N; Querellou S
Medicine (Baltimore); 2019 Jul; 98(29):e16417. PubMed ID: 31335691
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant-Intent Immunotherapy in Advanced, Resectable Cutaneous Squamous Cell Carcinoma.
Kim EY; Ruiz ES; DeSimone MS; Shalhout SZ; Hanna GJ; Miller DM; Schmults C; Rettig EM; Foreman RK; Sethi R; Thakuria M; Silk AW
JAMA Otolaryngol Head Neck Surg; 2024 May; 150(5):414-420. PubMed ID: 38546619
[TBL] [Abstract][Full Text] [Related]
9.
Hicks RJ; Iravani A; Sandhu S
PET Clin; 2020 Jan; 15(1):11-22. PubMed ID: 31735298
[TBL] [Abstract][Full Text] [Related]
10. Diagnostic performance of
Chaput A; Robin P; Podeur F; Ollivier M; Keromnes N; Tissot V; Nonent M; Salaün PY; Rousset J; Abgral R
Laryngoscope; 2018 Feb; 128(2):378-385. PubMed ID: 28600822
[TBL] [Abstract][Full Text] [Related]
11. The predictive value of
Mattoli MV; Massaccesi M; Castelluccia A; Scolozzi V; Mantini G; Calcagni ML
Radiat Oncol; 2017 Jan; 12(1):4. PubMed ID: 28057034
[TBL] [Abstract][Full Text] [Related]
12. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
13. Cancer immunotherapy is accompanied by distinct metabolic patterns in primary and secondary lymphoid organs observed by non-invasive
Schwenck J; Schörg B; Fiz F; Sonanini D; Forschner A; Eigentler T; Weide B; Martella M; Gonzalez-Menendez I; Campi C; Sambuceti G; Seith F; Quintanilla-Martinez L; Garbe C; Pfannenberg C; Röcken M; la Fougere C; Pichler BJ; Kneilling M
Theranostics; 2020; 10(2):925-937. PubMed ID: 31903160
[No Abstract] [Full Text] [Related]
14. 15-Year Experience of 18F-FDG PET Imaging in Response Assessment and Restaging After Definitive Treatment of Merkel Cell Carcinoma.
Byrne K; Siva S; Chait L; Callahan J; Bressel M; Seel M; MacManus MP; Hicks RJ
J Nucl Med; 2015 Sep; 56(9):1328-33. PubMed ID: 26159592
[TBL] [Abstract][Full Text] [Related]
15. A prospective trial comparing FDG-PET/CT and CT to assess tumor response to cetuximab in patients with incurable squamous cell carcinoma of the head and neck.
Adkins D; Ley J; Dehdashti F; Siegel MJ; Wildes TM; Michel L; Trinkaus K; Siegel BA
Cancer Med; 2014 Dec; 3(6):1493-501. PubMed ID: 25081631
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of
Lee JR; Almuhaimid TM; Roh JL; Oh JS; Kim SJ; Kim JS; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2018 Sep; 118(4):644-650. PubMed ID: 30132891
[TBL] [Abstract][Full Text] [Related]
17. Correlation between fluorodeoxyglucose hotspots on pretreatment positron emission tomography/CT and preferential sites of local relapse after chemoradiotherapy for head and neck squamous cell carcinoma.
Chaput A; Calais J; Robin P; Thureau S; Bourhis D; Modzelewski R; Schick U; Vera P; Salaün PY; Abgral R
Head Neck; 2017 Jun; 39(6):1155-1165. PubMed ID: 28263422
[TBL] [Abstract][Full Text] [Related]
18. Association of post-treatment positron emission tomography with locoregional control and survival after radiation therapy for squamous cell carcinoma of the vulva.
Rao YJ; Hassanzadeh C; Chundury A; Hui C; Siegel BA; Dehdashti F; DeWees T; Mullen D; Powell MA; Mutch DG; Schwarz JK; Grigsby PW
Radiother Oncol; 2017 Mar; 122(3):445-451. PubMed ID: 28063696
[TBL] [Abstract][Full Text] [Related]
19. Utility of (18)F-FDG PET/CT in patients with advanced squamous cell carcinoma of the uterine cervix receiving concurrent chemoradiotherapy: a parallel study of a prospective randomized trial.
Liu FY; Lai CH; Yang LY; Wang CC; Lin G; Chang CJ; Chang WY; Huang SH; Huang YE; Peng NJ; Hong JH; Chao A; Chou HH; Chang YC; Yen TC
Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1812-23. PubMed ID: 27160224
[TBL] [Abstract][Full Text] [Related]
20. Clinical Value of
Hynninen J; Laasik M; Vallius T; Kemppainen J; Grönroos S; Virtanen J; Casado J; Hautaniemi S; Grenman S; Seppänen M; Auranen A
Clin Oncol (R Coll Radiol); 2018 Aug; 30(8):507-514. PubMed ID: 29753662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
